IL17A and blastomycosis: These results are in marked contrast to what was observed with an attenuated Blastomyces dermatitidis vaccine which protected CD4+ T cell-deficient mice against blastomycosis and histoplasmosis by eliciting IL-17-producing CD8+ T cells (Tc17)37.